Super-Sized Medtech Rounds Scarce, But Growing
This article was originally published in Start Up
Executive Summary
The number of big medtech venture rounds, those worth at least $50 million, has decreased and plateaued over the past couple of years, but the overall dollars brought in by those scarce deals notably increased in 2015. And a few lucky medtech firms managed to grab more than $100 million from single fundraises last year.
You may also be interested in...
Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.
Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings
Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.